Valuation : NeoGenomics, Inc.

Market Cap 2.23B 1.92B 1.8B 1.64B 3.1B 213B 3.11B 21.28B 8.25B 107B 8.38B 8.2B 356B P/E 2026 *
-58.2x
P/E 2027 * -71.1x
Enterprise Value 2.23B 1.92B 1.8B 1.64B 3.1B 213B 3.11B 21.28B 8.25B 107B 8.38B 8.2B 356B EV / Sales 2026 *
2.78x
EV / Sales 2027 * 2.52x
Free-Float
96.15%
Yield 2026 *
-
Yield 2027 * -
1 day+3.45%
1 week+4.29%
Current month+13.60%
1 month+25.05%
3 months+87.38%
6 months+70.80%
Current year+47.70%
1 week 16.21
Extreme 16.21
17.46
1 month 13.05
Extreme 13.05
17.46
Current year 7.06
Extreme 7.065
17.46
1 year 6.94
Extreme 6.945
17.46
3 years 4.72
Extreme 4.72
21.22
5 years 4.72
Extreme 4.72
54.74
10 years 4.72
Extreme 4.72
61.57
Manager TitleAgeSince
Chief Executive Officer 65 2025-03-31
Director of Finance/CFO 57 2026-03-01
President 53 2025-03-31
Director TitleAgeSince
Chairman 64 2021-10-06
Director/Board Member 63 2017-07-18
Director/Board Member 69 2020-07-14
Date Insider Type Main position Quantity % Market Cap.
8/21/26 Fiscal year

Chairperson

67,272 0.0517%
8/4/26 Sell

Controller/Auditor

-20,000 0.0154%
6/23/26 Free

Director

23,909 0.0184%
Change 5-day change 1-year change 3-year change Capi.($)
+3.45%+4.29%+159.25%+24.78% 2.23B
+0.52%+4.12%+104.24%+489.84% 48.79B
-0.58%+1.60%+20.57%+58.22% 27.23B
+0.20%-14.69%-15.69%-37.60% 7.1B
-0.51%+1.23%+8.36%+138.22% 6.02B
-0.05%+2.61%+17.06%+77.10% 3.39B
+3.30%+13.35%-28.49%+2,024.35% 2.69B
+0.11%+2.08%+31.87%+24.40% 1.97B
-1.45%+1.24%-7.80%-51.91% 1.94B
-1.82%-4.93%+17.02%-10.36% 1.73B
Average +0.32%+1.95%+30.64%+273.70% 10.31B
Weighted average by Cap. +0.18%+2.08%+58.18%+307.92%

Financials

2026 *2027 *
Net sales 804M 690M 648M 592M 1.12B 76.69B 1.12B 7.67B 2.97B 38.69B 3.02B 2.95B 128B 885M 760M 713M 651M 1.23B 84.42B 1.23B 8.44B 3.27B 42.59B 3.32B 3.25B 141B
Net income -39.05M -33.52M -31.46M -28.73M -54.23M -3.72B -54.49M -372M -144M -1.88B -147M -143M -6.22B -32.73M -28.09M -26.36M -24.08M -45.44M -3.12B -45.66M -312M -121M -1.57B -123M -120M -5.22B
Net Debt - -
Logo NeoGenomics, Inc.
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing, interpretation and consultative services, molecular and NGS testing, comprehensive technical and professional services offering, clinical trials and research, validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Molecular testing and others.
Employees
2,500
Date Price Change Volume
26-08-26 US$17.37 +3.45% 1,682,451
26-08-25 US$16.79 +2.32% 872,112
26-08-24 US$16.41 -3.36% 1,096,237
26-08-21 US$16.98 +2.72% 1,139,873
26-08-20 US$16.53 -0.75% 2,748,216
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
17.37USD
Average target price
19.72USD
Spread / Average Target
+13.54%

Quarterly revenue - Rate of surprise